Latest Diagnostics News

Optiscan Imaging has fast-tracked Stage 2 of its pioneering head and neck cancer imaging study, moving into live intraoperative imaging ahead of schedule. This advancement supports FDA regulatory efforts and enhances the company’s AI imaging development.

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

Botala Energy’s Pitse Pilot well 3.5B in Botswana has successfully completed hydraulic stimulation and entered commercial production testing, marking a critical step toward establishing gas flow rates above 70 GJ/day.

Imricor Medical Systems has submitted its final 510(k) devices to the FDA, marking a major step towards commercialising its MRI-guided cardiac catheterisation platform in the US.

AnteoTech has secured independent validation for its Ultranode™ 95 silicon anode in commercial drone battery cells, launched a new battery additive, and strengthened its cash position with a A$10 million capital raise.

PainChek appoints seasoned US medtech executive Karen Holzberger as CEO to spearhead growth following FDA clearance and major US contracts.

EMVision Medical Devices has hit key enrolment milestones in its pivotal brain scanner trial, expanded clinical endpoints, and maintained a strong cash position with $17.1 million on hand.

INOVIQ Ltd has revealed significant sample quality problems in its EXO-OC ovarian cancer diagnostic study, prompting a technical review and a refined development approach while maintaining its dual commercialisation strategy.

Cleo Diagnostics (ASX:COV) has entered the analytical validation phase for its ovarian cancer test, progressing toward an FDA 510(k) submission expected in early 2027.

INOVIQ Limited hit a roadblock in expanding clinical validation of its EXO-OC™ ovarian cancer test due to unsuitable biobank samples, yet improved its diagnostic algorithm and progressed its CAR-exosome therapeutic program, maintaining a solid cash position of A$9.35 million.

Archer Materials made significant strides in quantum chip fabrication and quantum neural network fraud detection, while progressing its Biochip beta prototype. A $7 million placement post-quarter strengthens its financial position to accelerate development and commercialisation.

Proteomics International has won a key US patent for its PromarkerEndo blood test, bolstering its commercial foothold in the world’s largest healthcare market. The patented technology offers a non-invasive, accurate diagnosis of endometriosis, a condition that currently takes years to detect.